91 results about "Lymphatic metastasis" patented technology

The present invention is one kind of reagent for quick immune histohcemical detection of lymphatic metastasis of mammary cancer and corresponding detecting method. Several kinds of directly marked antibody capable of distinguishing metastatic cancer cell and inherent lymph node cell are mixed into reagent and one-step reacted to stain the metastatic cancer cell in lymph node specifically. The present invention is used in the fast pathological diagnosis of early lymphatic metastasis of mammary cancer, and has raised sensitivity, high accuracy and high specificity.

The invention provides a processing method and device for a pathological image of lymphatic metastasis of a breast cancer. The method comprises: S1, an example image is obtained and example image calibration information corresponding to the example image is obtained; S2, according to the example image and the example image calibration information, a training sample set is generated; S3, deep learning network training and parameter optimization are carried out based on the training sample set to obtain a convolutional neural network model; and S4, a testing image is tested by using the convolutional neural network model and a target area is detected. According to the processing method and device, automatic image classification is realized by using the deep learning technology; technical problems of poor consistency and low accuracy of the manual film reading and classification work are solved; the work efficiency is improved; and the probability of errors is reduced.

The present invention relates to a neuropilin-1 ligand polypeptide-polyethylene glycol-phospholipid composite, its active targeting liposome vector system and a preparation method thereof. The liposome vector system comprises the following components: a: phospholipid, b: cholesterol, c: methoxy polyethylene glycol-phospholipid composite (with the molecular weight of methoxy polyethylene glycol ranging from 400 to 6000), and d: a RPAKPAR sequence-containing polypeptide-polyethylene glycol-phospholipid composite (with the molecular weight of polyethylene glycol ranging from 400 to 8000). And for the components, a and b are in a molar ratio of 5:1-1:5, a and c are in a molar ratio of 1000:1-1000:100, and a and d are in a ratio of 1000:0.1-1000:100. The system can make a liposome passively drained into a lymphatic system through subcutaneous interstitial injection or intramuscular injection, and can make the liposome targeted to a lymphatic metastasis lesion through the mediation effect of RPAKPAR. The system can also make the liposome targeted to a primary tumor and a hematogenous metastasis lesion directly through intravenous injection administration, through a tumor EPR (electron paramagnetic resonance) effect and the mediation effect of RPAKPAR. The liposome vector system of the invention can be used for targeted drug delivery in diagnosis or treatment of prostate cancer primary tumors and metastatic tumors.

The invention belongs to the fields of polypeptides, high-polymer materials and pharmaceutics, and relates to an amido bond cyclized polypeptide c(LyP-1) and an application thereof to a tumor active targeting nano-delivery system. The sequence of the c(LyP-1) is CGNKRTRGA, and a high-polymer carrier material modified by the c(LyP-1) is constructed into a nano-delivery system. As proved by experimental results, the cyclic nonapeptide c(LyP-1) cyclized by an amido bond has higher blood stability, receptor protein binding activity and tumor cell affinity activity than a cyclic nonapeptide (LyP-1) cyclized by using a disulfide bond. A nano-delivery system lipidosome and the like constructed by the high-polymer carrier material modified by the c(LyP-1) have higher tumor tissue targeting properties and better tumor growth resisting effects, and can be used for restraining the regeneration of tumor lymphatic vessels more effectively and preventing the lymphatic metastasis of tumors. As a targeting molecule which can be used for mediating the nano-delivery system in targeting tumor resistance and prevention of tumor lymphatic metastasis, the c(LyP-1) has a good application prospect.

The invention discloses a molecular marker for diagnosing and treating the bladder cancer, namely LncRNA DANCR, and also discloses application of the molecular marker to screening or preparation of reagents used for diagnosing the bladder cancer diagnosing, bladder cancer lymphatic metastasis, bladder cancer prognosis relapse or bladder cancer clinical stages and application of the molecular marker to screening or preparation of drugs used for treating the bladder cancer. It is found that the LncRNA DANCR has high expression in bladder cancer cases with lymphatic metastasis, has negative correlation with overall survival prognosis of a patient and is an independent indicator for diagnosing the bladder cancer and judging bladder cancer development and survival prognosis; silencing of the LncRNA DANCR can restrain in-vitro proliferation, cell migration and invasion and in-vivo tumor formation and lymphatic metastasis of bladder cancer cells. It is verified that the LncRNA DANCR is an important cancerigenic factor of the bladder cancer for the first time, and can be used as a molecular marker for bladder cancer prognosis diagnosis and a new target spot for treatment.

The invention belongs to the field of molecule biological medicine, and relates to a magnetic polyacrylic acid-modified nanometer pipe and a method for preparing the same. A multi-wall carbon nanometer pipe is modified by polyacrylonitrile and hydrolyzed under acid condition to obtain a polyacrylic acid-modified water-soluble nanometer pipe containing large quantity of carboxyl groups; by the water-phase chemical co-precipitation method, a magnetic ferroferric oxide-polyacrylic acid-modified multi-wall carbon nanometer pipe composite with the diameter of between 10 and 80nm is prepared, and the composite has good lymphotaxis and strong magnetic response; tests show that a medicine carrier can effectively adsorb chemical treatment medicines to a lymphatic system, slowly release the chemical treatment medicines in a metastasis lymph node of a malignant tumor, has good magnetic field positioning effect and obviously inhibits the proliferation and metastasis of the tumor cell of the lymph node. The invention provides a novel intervention means for lymphatic metastasis of the malignant tumor.

The invention belongs to the field of microorganism animal cell lines, and particularly relates to a pancreatic cancer cell line with lymphatic channel high migration activity. According to the pancreatic cancer cell line with the lymphatic channel high migration activity, a human pancreatic cancer BxPC-3 cell line is adopted as source cells, by means of a nude mouse palmula subcutaneous vaccinization method, lymphatic metastasis oncocyte sunlines with different migration potentialities are separated from matrilineal BxPC-3 cells, a pancreatic cancer cell line BxPC-3-LN with the lymphatic channel high migration activity is screened out through experiments inside and outside human bodies, a storage number is CGMCC NO.5421, and the storage date is October 28th, 2011. The pancreatic cancer cell line with the lymphatic channel high migration activity is the same as the matrilineal BxPC-3 cells in the genetic background, is characterized by being strong in invasiveness, high in migration efficiency and concentrated in migration, provides a suitable experimental platform for research on pancreatic cancer migration mechanism and the screening of antineoplastic drugs, and has very important significance and wide application prospects.

The invention relates to an optimum mass spectrometry model and a preparation method thereof for detecting the feature protein of breast cancer, belonging to the field of mass spectrometry detection technique. The invention is characterized in that eight up-regulated proteins and three lower-regulated proteins are screened from the blood serum to be used as the feature proteins; any two or more proteins of the eleven proteins are chosen so as to establish a blood serum feature protein mass spectrometry model of identification with two in a group for patients with breast cancer and normal people, and patients with benign breast disease, lymphatic metastasis of breast cancer and remote metastasis of breast cancer according to the mass-charge ratio m / z of each protein peak and the critical peak average value of the protein; the preparation method of the invention provides a foundation for further discovering new breast cancer biological marks. The method of the invention is better than any single detection method adopted currently for the detection of the breast cancer, and provides a non-invasive technique for the early detection and early treatment of the breast cancer, thus providing a new method for reducing the mortality of the breast cancer, improving the cure rate of the breast cancer and screening and examining the breast cancer for high-risk population further.

The invention belongs to the field of pharmaceutical preparations, and relates to an active targeting liposome carrier system for in situ tumors and lymphatic metastatic tumors. The carrier system is composed of polypeptides and liposomes whose amino acid sequence is CGNKRTRGC sequence of LyP-1. Wherein the LyP-1 sequence polypeptide is connected by two cysteines through a disulfide bond to form a ring structure. The liposome carrier system can passively drain the liposome into the lymphatic system through subcutaneous interstitial injection or intramuscular injection, and target the tumor metastasis lymph node through the mediated effect of LyP-1. The system can also be administered directly via intravenous injection, targeting tumors in situ and lymphatic metastases through tumor EPR effects and LyP-1-mediated effects. The liposome carrier system of the present invention can be used for targeted delivery of drugs for the diagnosis or treatment of tumors in situ and lymphatic metastases.

The invention relates to hydrogel nanoparticles used as an injectable subcutaneous implant agent, which can effectively solves the problem of fulfilling an aim of realizing tumor treatment by locally injecting the hydrogel nanoparticles beside a subcutaneous tumor, changing the hydrogel nanoparticles into a gel and slowly releasing nanoparticles in vivo. The hydrogel nanoparticles are prepared from hydrogel solution and 2-methoxyl estradiol liposome nanoparticle powder or solid liposome nanoparticle powder by a method which comprises the following steps of: adding the 2-methoxyl estradiol liposome nanoparticle powder or the solid liposome nanoparticle powder into the hydrogel solution; and uniformly mixing to form the hydrogel nanoparticles which can be used as an injectable subcutaneous implant agent, wherein 100mg of the 2-methoxyl estradiol liposome nanoparticle powder is added into every 1ml of the hydrogel solution. The injectable hydrogel implant agent of the invention can be used for treating subcutaneous tumors such as breast cancer and the like, keep an effective medicament concentration in a local target site, can realize sustained release and controlled release, can avoid medicament resistance caused by long-term medication, simultaneously improve a curative effect and reduce dosage, reduce toxic and side effects on a whole body, and also can prevent lymphatic metastasis of the tumors such as the breast cancer and the like.

The invention discloses a multi-mode ferritin nanometer contrast agent based on ferritin and a preparation method thereof. Horse spleen ferritin with the targeted performance on macrophage surface scavenger receptors 5 is used as a biological nanometer template (shell); prussian blue nanometer particles are used as cores to realize MRI and photoacoustic imaging; next, fluorescent dye IR-782 is coupled to be used as a fluorescence probe part; the multi-mode ferritin nanometer contrast agent of a shell core structure is prepared. The multi-mode ferritin nanometer contrast agent combines the photoacoustic imaging, fluorescence imaging and MRI trimodal imaging, can be used for sentinel lymph node photoacoustic / MRI / fluorescence trimodal radiography before breast cancer, can also be used for performing blue dyeing on the sentinel lymph node before breast cancer by using the dyeing effect of the prussian blue, realizes the comprehensive and precise diagnosis of the breast cancer lymphatic metastasis, and promotes the development of clinic medicine and image diagnostics.

The invention discloses an MDM2 gene which is a novel predisposing gene of nasopharyngeal darcinoma by relating the SNP 309 polymorphic loci of the MDM2 gene with the risk of the nasopharyngeal darcinoma and the more serious lymph node metastasis, thereby providing new genetic counseling contents and the molecule criterion for people to prevent and control the nasopharyngeal darcinoma. In addition, the invention also relates to a method for detecting the SNP309 polymorphic loci and the corresponding detecting kit, wherein, the detecting method is the PCR product direct sequencing method that is the polymerase chain reaction-sequencing method.

The invention belongs to the field of pharmaceutical chemistry, relating to a folic acid-polyethyleneglycol composite which can be combined with imageology nuclide for tumor diagnosis, wherein the folic acid composite folic acid, the polyethyleneglycol, functional oligomerized polylysine and a plurality of DTPA are connected in a covalent bond mode. After applying the folic acid composite to animal nuclear magnetic resonance or radioactive video picture diagnosis, experiment results show that the type of the composite is lead to lymphatic system without transmitting blood capillaries at tissue spaces, is dynamically concentrated and eliminated at lymph glands, combines with high-expressive tumor cells of folate receptors in a competitiveness mode, and presents excellent lymph guiding property and accumulative property of tumor locations. The invention can be effectively used for target diagnosis of tumors and metastatic tumors of the lymphatic system, and has high targeting property and high resolution of the tumor and lymphoma diagnosis.

The invention provides a lymph gland targeted metastatic human hepatoma cell strain. The mother cell is a red fluorescent protein-expressed hepatoma cell HCCLM3-R. The human hepatoma cell strain is characterized in that the cell is named as lymph gland targeted metastatic human hepatoma cell strain HCCLM3-R-LnM1 according to the classified nomenclature with a preservation number of 3645, and has the following biological characteristics: the cell is polygonal epithelioid and is in adherent growth and loss of contact growth inhibition, is of a hypo-triploid karyotype, and has 50-58 of chromosomes each of which secretes AFP proteins. The establishing method comprises the following steps: using subcutaneous and liver orthotopic transplantation tumor models of a nude mouse to carry out spontaneous lymphatic metastasis screening, and then carrying out in-vitro cloning, amplification and purification on the lymphatic metastasis human hepatoma cell. The invention has wide application prospects and potential social and economic values in the basic research on hepatoma and the pre-clinic research on medicament.

The invention discloses an automatic classification method and system for breast cancer pathological sections, and the method comprises the steps: constructing a deep semantic segmentation network forthe semantic segmentation of pathological tissue sections, and obtaining a lesion region; constructing a morphological feature set according to the obtained lesion area; constructing a pathological tissue slice classification model based on the morphological feature set; and classifying the n pathological tissue sections of the patient by using the classification model, and calculating the pN stage of the patient according to the classification result of the n sections. According to the automatic classification method for the breast cancer pathological sections, the pN stages of lymphatic metastasis of patients can be automatically predicted, compared with an existing method that only lesion areas in the sections are segmented, the requirements of doctors for an intelligent diagnosis system are better met, and research and landing of an existing intelligent diagnosis method and system are promoted.

The invention belongs to the field of medicine, and particularly relates to new uses of a nanometer charcoal suspension injection, particularly to applications of the nanometer charcoal suspension injection in preparation of cancer diagnosis reagents and thermotherapy reagents matched with near-infrared light. According to the present invention, near-infrared light is used to heat the diagnosed tissue and the nanometer charcoal suspension injection can effectively absorb infrared rays to convert into heat, such that the great temperature difference between cancer cells and normal cells is produced; with a thermal imager, the cancer cells and the normal cells are distinguished, and the cancer cell distribution and the metastasis are adjusted, such that the new method for non-invasive diagnosis of cancer cell and malignant tumor draining lymph node cancer draining lymph node trending and distribution by using the nanometer charcoal suspension injection is provided for the public; and near-infrared ray is used to heat the place diagnosed as the cancer cell-containing tissue and location, such that the cancer cell temperature is rapidly increased, the cancer cells are subjected to high temperature killing at the temperature of about 50-56 DEG C, while the normal cells is at the human acceptable level in a short period so as to achieve the purposes of thermotherapy on the malignant tumor primary site and the draining lymph node metastasis.

The invention discloses a method for establishing a model of oral cancer and lymphatic metastasis of mice, which is characterized by including mouse selection and grouping, reagent preparation, mouse feeding, experimental observation and conclusion drawing. The method specifically includes: using 200mg / L 4-nitroquinoline-1-oxide to feed Balb / c (Bagg albino / c) mice for 20 weeks by a drinking method; continuously using tap water to feed the mice to the fortieth week and observing to the fortieth week; obtaining the model of oral cancer and lymphatic metastasis of the mice which have development metastasis extremely similar to human oral cancer, namely location diversification, a full metastasis process of normal mucosa, dysplasia, carcinoma in situ, squamous carcinoma and cervical lymph nodes. The method is simple, natural and ideal in effect, guarantees high morbidity, diversified disease locations (lip, palate, gum, tongue and mouth floor) and high submandibular lymph node metastasis rate, and a novel powerful tool for preventing and treating human oral cancer is provided.

The present invention relates to the technical field of medicine and particularly relates to an antitumor lymphatic metastasis function of mitoxantrone and a pharmaceutical preparation of the mitoxantrone. The mitoxantrone is administered locally, such as intratumoral administration and peritumoral and tumor subcutaneous administration. The mitoxantrone can be prepared into the clinically acceptable pharmaceutical preparation with a pharmaceutically acceptable carrier. The pharmaceutical preparation is a parenteral administration preparation. The parenteral administration preparation is selected from a solution, a liposome, a dendritic macromolecule, a nanoparticle, a nanocrystal, a microcrystal, a microsphere and a gel agent. The mitoxantrone is used for local chemotherapy to increase anti-tumor activity, reduces toxic and side effects, targets a lymphatic system, inhibits tumor lymphatic metastasis, can reduce tumor volume and is convenient for subsequent surgical resection when usedfor neoadjuvant chemotherapy, can also kills tumor cells metastasized in lymphatic vessels, reduces risks of postoperative tumor recurrence, and improves quality of life of patients.

The invention discloses an application of EB virus encoded microRNA BART10 (EBV-miR-BART10) in preparing a prediction preparation for recurrence and metastasis of nasopharyngeal carcinoma. The research proves that the expression level of EBV-miR-BART10 in the nasopharyngeal carcinoma tissue is in positive correlation with the lymphatic metastasis and the distant metastasis of the nasopharyngeal carcinoma patient; if the expression of the EBV-miR-BART10 in the nasopharyngeal carcinoma tissue is up-regulated, the nasopharyngeal carcinoma patient with higher EBV-miR-BART10 expression have larger possibilities of recurrence and metastasis than the nasopharyngeal carcinoma patient with lower EBV-miR-BART10 expression, and the prognosis is worse, therefore, the application of the expression of the EBV-miR-BART10 in the predication of recurrence and metastasis of the nasopharyngeal carcinoma patient can provide powerful biomolecular basis for the prognosis of the nasopharyngeal carcinoma patient, and thus the application method has profound clinical significances and important popularization and application prospects.

The invention discloses a colorectal cancer metastasis detection primer and a colorectal cancer metastasis detection kit based on serum exosomal microRNAs. According to the primer and the kit, the serum exosomal microRNAs differential expression profiles of colorectal cancer patients suffering from lymphatic metastasis and colorectal cancer patients not suffering from lymphatic metastasis are screened by adopting a second-generation high-throughput sequencing technology, then miR-483-5p with the most obvious up-regulation expression and miR-451a with the obvious down-regulation expression are subjected to large sample verification, and the result shows that miR-483-5p and miR-451a have the good identification and diagnostic efficiencies for colorectal cancer lymphatic metastasis. Meanwhile, combined miR-191-5p and U6 are taken as reference genes for carrying out relative quantification analysis on miR-483-5p and miR-451a in a sample, so that the data accuracy is improved. According to the primer and the kit, the amplification efficiency (E) is calculated according to the formula E=10<(-1 / Slope)>-1, the expression quantities of miR-483-5p and miR-451a relative to miR-191-5p and U6 are calculated according to the formula Q=(E+1)<-delta Cq>, so that the restriction that in the traditional 2<-delta delta Cq> method, the PCR amplification efficiency needs to be 100% is broken through, and the result analysis is relatively reliable.

The invention discloses a set of markers used for early gastric cancer diagnosis. The markers are composed of INHBA and SPP1. The invention also discloses application of the INHBA and the SPP1 in preparing a kit for early gastric cancer diagnosis and a kit for predicting lymphatic metastasis status of a gastric cancer patient. The expression quantities of the INHBA and SPP1 are detected by adopting a semi-quantitative fluorescence real-time enzyme-linked reaction method, and compared with traditional pathological cytology detection, the detection of molecular markers has the advantages of small required sample size, specificity, sensitivity, accuracy, high repeatability, automation and the like. The molecular markers lay an ideal clinical application basis for the early gastric cancer diagnosis and the prediction of the lymphatic metastasis.

The invention relates to an optimum mass spectrometry model and a preparation method thereof for detecting the feature protein of nasopharyngeal cancer, belonging to the field of mass spectrometry detection technique. The invention is characterized in that six up-regulated proteins and five lower-regulated proteins are screened from the blood serum to be used as the feature proteins; any two or more proteins of the eleven proteins are chosen so as to establish a blood serum feature protein mass spectrometry model of identification with two in a group for patients with nasopharyngeal cancer and normal people, and patients with benign nasopharyngeal cancer disease, lymphatic metastasis of nasopharyngeal cancer and remote metastasis of nasopharyngeal cancer according to the mass-charge ratio m / z of each protein peak and the critical peak average value of the protein; the preparation method of the invention provides a foundation for discovering new nasopharyngeal cancer biological marks. The method of the invention is better than any single detection method adopted currently for the detection of the nasopharyngeal cancer, and provides a non-invasive technique for the early detection and early treatment of the nasopharyngeal cancer, thus providing a new method for reducing the mortality of the nasopharyngeal cancer, improving the cure rate of the nasopharyngeal cancer and screening and examining the nasopharyngeal cancer for high-risk population further.

The invention relates to an optimum mass spectrometry model and a preparation method thereof for detecting the feature protein of renal cancer, belonging to the field of mass spectrometry detection technique. The invention is characterized in that seven up-regulated proteins and three lower-regulated proteins are screened from the blood serum to be used as the feature proteins; any two or more proteins of the ten proteins are chosen so as to establish a blood serum feature protein mass spectrometry model of identification with two in a group for patients with renal cancer and normal people, and patients with benign renal cancer disease, lymphatic metastasis of renal cancer and remote metastasis of renal cancer according to the mass-charge ratio m / z of each protein peak and the critical peak average value of the protein; the preparation method of the invention provides a foundation for discovering new renal cancer biological marks. The method of the invention is better than any single detection method adopted currently for the detection of the renal cancer, and provides a non-invasive technique for the early detection and early treatment of the renal cancer, thus providing a new method for reducing the mortality of the renal cancer, improving the cure rate of the renal cancer and screening and examining the renal cancer for high-risk population further.

The invention discloses a small molecule marker for predicting lymphatic metastasis of lung cancer and application to diagnosis, and discloses a composition for predicting the lymphatic metastasis ofthe lung cancer. The small molecule marker at least comprises phosphatidylinositol (18:3 / 0:0), and preferably comprises phosphatidylinositol (18:3 / 0:0), lysophosphatidylcholine (18:1) and phenylalanine, wherein the phosphatidylinositol (18:3 / 0:0) is used for singly diagnosing that the AUC (area under the curve) of the lymphatic metastasis of the lung cancer and the non-lymphatic metastasis of thelung caner is 0.803, and the accuracy is medium; the phosphatidylinositol (18:3 / 0:0), the lysophosphatidylcholine (18:1) and the phenylalanine are used for jointly diagnosing that the AUC of the lymphatic metastasis of the lung cancer and the non-lymphatic metastasis of the lung caner is 0.937, and the accuracy is higher; the sensitivity and specificity at the optimum diagnosis critical value respectively reach 0.9 or above. After centralized further verifying by independent samples, the small molecule marker has the advantages that the accuracy of the phosphatidylinositol (18:3 / 0:0), the lysophosphatidylcholine (18:1) and the phenylalanine for jointly diganosing the lymphatic metastasis of the lung cancer and the non-lymphatic metastasis of the lung caner reaches 95%, and the clinical value is higher.

The invention relates to the molecular diagnosis field and relates to a molecular diagnosis method and reagent for non-invasive detection of prostate cancer and lymphatic metastasis of prostate cancerby virtue of urine. The method comprises the following steps: extracting and purifying urine nucleic acid; (2) carrying out DNA hydrosulphite conversion reaction and subsequent purification; (3) detecting a plurality of gene promoter regions by virtue of methylation-specific real-time fluorescence PCR; and (4) analyzing multiple gene results, wherein the steps (1) and (2) can be combined into onestep, and multiple genes contain the promoter regions of the following genes: CRMP4, PITX2, RASSF1A, SOSTDC, CYBA, EFEMP1, KNM5D, GSTP1, WFDC2, TACSTD2 and the like. By combining the detection results of the genes, the diagnosis of prostate cancer and the lymphatic metastasis of prostate cancer can be realized.

The invention relates to a grading model for detecting lymphoma and lymphatic metastatic cancer and application of the grading model. According to the model, change of imprinting genes in lymphoma andlymphatic metastatic cancer is graded by calculating imprinting gene deletion expression quantity, imprinting gene copy number abnormal expression quantity and imprinting gene total expression quantity. The expression of imprint deletion on tissues and cell samples of lymphoma and cancer lymphatic metastasis patients is represented by an intuitive method; through an imprinting gene in-situ labeling method, the change of imprinting genes can be objectively, visually, early and accurately detected, the quantitative model can be provided, and great contribution is made to diagnosis of lymphoma and lymphatic metastatic cancer.

The invention relates to a fixing treatment method of tumor lymph node specimen in vitro and belongs to the technical field of detection specimen preparation. The method includes: performing fat softening treatment to an in-vitro specimen in a stationary liquid, performing adipocyte permeability enhancement treatment, and treating the specimen at constant temperature 35-39 DEG C for 2-6 h with a digestion liquid. The fat softening treatment is carried out by soaking the specimen at room temperature in the stationary liquid for 2-24 h. The immobilizing liquid includes formaldehyde, lecithin, anhydrous ethanol and acetone according to the concentrations of 50-150 ml / L of the formaldehyde, 30-70 g / L of the lecithin, 200-300 ml / L of the anhydrous ethanol and 200-300 ml / L of the acetone. The treatment method is applied to treatment on tumor lymph node specimen in vitro, and can increase the detection number of lymph nodes and has accuracy in lymphatic metastasis positive rate.

The invention provides an establishing method for a rabbit tongue carcinoma model. The method comprises the following steps: establishing rabbit tongue squamous carcinoma cell lines; inoculating the rabbit tongue squamous carcinoma cells under skin of a nude mouse and culturing the nude mouse; taking cultured nude mouse subcutaneous tumor tissue, and inoculating the subcutaneous tumor tissue on a rabbit tongue, to establish a rabbit tongue carcinoma model; based on the rabbit tongue carcinoma model, establishing a high lymph gland metastatic rabbit tongue carcinoma animal model. Establishing a tongue carcinoma animal model with high lymph gland metastatic potential completely re-represents clinical characteristics of tongue carcinoma and lymphatic metastasis biological characteristics, and provides better experimental basis for prevention and treatment of tongue carcinoma. The method can be used for sensitivity evaluation of anti-tumor chemotherapeutics, and can also be used for research of radiotherapy, endocrinotherapy, immunological therapy, molecular targeting treatment, and other new treatment means.

The invention relates to hydrogel nanoparticles used as an injectable subcutaneous implant agent, which can effectively solves the problem of fulfilling an aim of realizing tumor treatment by locally injecting the hydrogel nanoparticles beside a subcutaneous tumor, changing the hydrogel nanoparticles into a gel and slowly releasing nanoparticles in vivo. The hydrogel nanoparticles are prepared from hydrogel solution and 2-methoxyl estradiol liposome nanoparticle powder or solid liposome nanoparticle powder by a method which comprises the following steps of: adding the 2-methoxyl estradiol liposome nanoparticle powder or the solid liposome nanoparticle powder into the hydrogel solution; and uniformly mixing to form the hydrogel nanoparticles which can be used as an injectable subcutaneous implant agent, wherein 100mg of the 2-methoxyl estradiol liposome nanoparticle powder is added into every 1ml of the hydrogel solution. The injectable hydrogel implant agent of the invention can be used for treating subcutaneous tumors such as breast cancer and the like, keep an effective medicament concentration in a local target site, can realize sustained release and controlled release, can avoid medicament resistance caused by long-term medication, simultaneously improve a curative effect and reduce dosage, reduce toxic and side effects on a whole body, and also can prevent lymphatic metastasis of the tumors such as the breast cancer and the like.

The invention discloses application of EIF5A2 to preparation of an esophageal squamous cell carcinoma prognosis reagent. Real-time quantitative PCR (Polymerase Chain Reaction) detection data shows that expression of the EIF5A2 in esophageal squamous cell carcinoma tissues is obviously higher than that in corresponding non-tumor tissues. An immunohistochemical data analysis result shows that expression of the EIF5A2 is positively correlated to lymphatic metastasis, the tumor invasion depth and neoplasm staging. Kaplan-Meier analysis shows that a patient overexpressed by the EIF5A2 has poor overall survival (p is less than 0.001). Multivariate analysis also proves that the EIF5A2 is an independent prognostic factor. The EIF5A2 possibly takes important effects in invasion and metastasis of esophageal squamous cell carcinoma. Further experimental data proves that overexpression of the EIF5A2 can be caused by gene amplification and oxygen deprivation; the EIF5A2 can be combined into a promoter region of HIF1a to up-regulate expression of the HIF1a; and the EIF5A2 can induce epithelial-mesenchymal transition conversion and promote angiopoiesis of the esophageal squamous cell carcinoma so as to promote invasion and metastasis of the esophageal squamous cell carcinoma. Knockout of the EIF5A2 can obviously inhibit tumor metastasis and the silent EIF5A2 is expected to be a potential target of esophageal squamous cell carcinoma treatment.